IDEAYA Biosciences announced positive topline results from the Phase 2/3 OptimUM-02 trial of darovasertib combined with crizotinib for first-line HLA*A2-negative metastatic uveal melanoma, showing a 58% reduction in disease progression risk and improved progression-free survival. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026, aiming for accelerated approval under the Real-Time Oncology Review program. Additional clinical updates for other pipeline candidates are expected in H2 2026, and IDEAYA maintains a strong cash reserve of approximately $973 million, supporting operations into 2030.
A three-day online training on Pharmaceutical Regulatory Affairs in Asia is scheduled for October 20-22, 2026, aiming to help professionals understand diverse regulatory requirements across major Asian markets including China, India, Korea, and ASEAN...
The global workwear market, valued at $265.12 billion in 2025, is expected to grow to $344.71 billion by 2031 with a 4.5% CAGR. Growth is fueled by rising corporate employment worldwide, especially in Asia-Pacific, and increased focus on professional...
The global microalgae-based aquafeed market is projected to grow from $320 million in 2026 to $481 million by 2031, at an 8.5% CAGR. Key growth drivers include rapid cost reductions in closed photobioreactor farming, making algae competitive with fis...
The global consumer finance market is projected to expand from $9.87 trillion in 2025 to $14.08 trillion by 2031, growing at a 6.17% CAGR. Key growth drivers include embedded finance at point-of-sale, which boosts credit uptake by integrating lending...
Xcel Brands has signed a licensing agreement with KBL Group to produce ready-to-wear collections for OFF/DUTY by Coco Rocha, a fashion brand created with supermodel Coco Rocha. KBL Group will handle sourcing, product development, manufacturing, and s...
